SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Mpagama SG)
 

Sökning: WFRF:(Mpagama SG) > Prospective evaluat...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003939naa a2200565 4500
001oai:prod.swepub.kib.ki.se:144456647
003SwePub
008240701s2020 | |||||||||||000 ||eng|
024a http://kipublications.ki.se/Default.aspx?queryparsed=id:1444566472 URI
024a https://doi.org/10.1136/bmjopen-2019-0353502 DOI
040 a (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a van den Elsen, SHJ4 aut
2451 0a Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort study
264 c 2020-06-16
264 1b BMJ,c 2020
520 a Global multidrug-resistant tuberculosis (MDR-TB) treatment success rates remain suboptimal. Highly active WHO group A drugs moxifloxacin and levofloxacin show intraindividual and interindividual pharmacokinetic variability which can cause low drug exposure. Therefore, therapeutic drug monitoring (TDM) of fluoroquinolones is recommended to personalise the drug dosage, aiming to prevent the development of drug resistance and optimise treatment. However, TDM is considered laborious and expensive, and the clinical benefit in MDR-TB has not been extensively studied. This observational multicentre study aims to determine the feasibility of centralised TDM and to investigate the impact of fluoroquinolone TDM on sputum conversion rates in patients with MDR-TB compared with historical controls.Methods and analysisPatients aged 18 years or older with sputum smear and culture-positive pulmonary MDR-TB will be eligible for inclusion. Patients receiving TDM using a limited sampling strategy (t=0 and t=5 hours) will be matched to historical controls without TDM in a 1:2 ratio. Sample analysis and dosing advice will be performed in a centralised laboratory. Centralised TDM will be considered feasible if >80% of the dosing recommendations are returned within 7 days after sampling and 100% within 14 days. The number of patients who are sputum smear and culture-negative after 2 months of treatment will be determined in the prospective TDM group and will be compared with the control group without TDM to determine the impact of TDM.Ethics and disseminationEthical clearance was obtained by the ethical review committees of the 10 participating hospitals according to local procedures or is pending (online supplementary file 1). Patients will be included after obtaining written informed consent. We aim to publish the study results in a peer-reviewed journal.Trial registration numberClinicalTrials.gov Registry (NCT03409315).
700a Sturkenboom, MGG4 aut
700a Akkerman, O4 aut
700a Barkane, L4 aut
700a Bruchfeld, Ju Karolinska Institutet4 aut
700a Eather, G4 aut
700a Heysell, SK4 aut
700a Hurevich, H4 aut
700a Kuksa, L4 aut
700a Kunst, H4 aut
700a Kuhlin, Ju Karolinska Institutet4 aut
700a Manika, K4 aut
700a Moschos, C4 aut
700a Mpagama, SG4 aut
700a Torrico, MM4 aut
700a Skrahina, A4 aut
700a Sotgiu, G4 aut
700a Tadolini, M4 aut
700a Tiberi, S4 aut
700a Volpato, F4 aut
700a van der Werf, TS4 aut
700a Wilson, MR4 aut
700a Zuniga, J4 aut
700a Touw, DJ4 aut
700a Migliori, GB4 aut
700a Alffenaar, JW4 aut
710a Karolinska Institutet4 org
773t BMJ opend : BMJg 10:6, s. e035350-q 10:6<e035350-x 2044-6055
856u https://bmjopen.bmj.com/content/bmjopen/10/6/e035350.full.pdf
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:144456647
8564 8u https://doi.org/10.1136/bmjopen-2019-035350

Hitta via bibliotek

  • BMJ open (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy